Mechanisms and effects of loss of human leukocyte antigen class II expression in immune-privileged site-associated B-cell lymphoma

Clinical Cancer Research

Volumn 12, Issue 9, 2006, Pages 2698-2705

  Booman, Marije ^a   Douwes, Jenny ^a   Glas, Annuska M ^b   Riemersma, Sietske A ^d   Jordanova, Ekaterina S ^d   Kok, Klaas ^a   Rosenwald, Andreas ^e   De Jong, Daphne ^c   Schuuring, Ed ^a   Kluin, Philip M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Agendia NV   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 2; HLA DR ANTIGEN; MESSENGER RNA;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; B CELL LYMPHOMA; CONTROLLED STUDY; DOWN REGULATION; GENE DELETION; GENE EXPRESSION; HEMIZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE ACTIVATION; MACROPHAGE; PRIORITY JOURNAL; T LYMPHOCYTE; TESTIS TUMOR; TUMOR IMMUNITY;

CENTROMERE; CHROMOSOMES, HUMAN, PAIR 6; GENE EXPRESSION REGULATION, NEOPLASTIC; HLA-D ANTIGENS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPH NODES; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SEQUENCE DELETION; TELOMERE; TESTIS;

EID: 33646719056     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2617     Document Type: Article

References (32)

1. Fonseca R, Habermann TM, Colgan JP, et al. Testicular lymphoma is associated with a high incidence of extranodal recurrence. Cancer 2000;88:154-61.
2. Zucca E, Conconi A, Mughal TI, et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol 2003;21:20-7.
3. Riemersma SA, Jordanova ES, Schop RF, et al. Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune- privileged sites. Blood 2000;96:3569-77.
4. Jordanova ES, Riemersma SA, Philippo K, Giphart-Gassler M, Schuuring E, Kluin PM. Hemizygous deletions in the HLA region account for loss of heterozygosity in the majority of diffuse large B-cell lymphomas of the testis and the central nervous system. Genes Chromosomes Cancer 2002;35:38-48.
5. Jordanova ES, Riemersma SA, Philippo K, Schuuring E, Kluin PM. Beta2-microglobulin aberrations in diffuse large B-cell lymphoma of the testis and the central nervous system. Int J Cancer 2003;103:393-8.
6. Jordanova ES, Philippo K, Giphart MJ, Schuuring E, Kluin PM. Mutations in the HLA class II genes leading to loss of expression of HLA-DR and HLA-DQ in diffuse large B-cell lymphoma. Immunogenetics 2003;55:203-9.
7. Riemersma SA, Oudejans JJ, Vonk MJ, et al. High numbers of tumour-infiltrating activated cytotoxic T lymphocytes, and frequent loss of HLA class I and II expression, are features of aggressive B cell lymphomas of the brain and testis. J Pathol 2005;206:328-36.
8. Rimsza LM, Roberts RA, Miller TP, et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood 2004;103:4251-8.
9. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-92.
10. Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon (France): IARC Press; 2001.
11. Stam NJ, Vroom TM, Peters PJ, Pastoors EB, Ploegh HL. HLA-A- and HLA-B-specific monoclonal antibodies reactive with free heavy chains in Western blots, in formalin-fixed, paraffin-embedded tissue sections and in cryo-immuno-electron microscopy. Int Immunol 1990;2:113-25.
12. Vaandrager JW, Schuuring E, Raap T, Philippo K, Kleiverda K, Kluin P. Interphase FISH detection of BCL2 rearrangement in follicular lymphoma using breakpoint-flanking probes. Genes Chromosomes Cancer 2000;27:85-94.
13. Fiegler H, Carr P, Douglas EJ, et al. DNA microarrays for comparative genomic hybridization based on DOP-PCR amplification of BAC and PAC clones. Genes Chromosomes Cancer 2003;36:361-74.
14. Kok K, Dijkhuizen T, Swart YE, et al. Application of a comprehensive subtelomere array in clinical diagnosis of mental retardation. Eur J Med Genet 2005;48:250-62.
15. Glas AM, Kersten MJ, Delahaye LJ, et al. Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood 2005;105:301-7.
16. Weigelt B, Glas AM, Wessels LFA, et al. Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci U S A 2003;100:15901-5.
17. Yang YH, Dudoit S, Luu P, et al. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 2002;30:e15-1.
18. Hughes TR, Marton MJ, Jones AR, et al. Functional discovery via a compendium of expression profiles. Cell 2000;102:109-26.
19. Sturn A, Quackenbush J, Trajanoski Z. Genesis: cluster analysis of microarray data. Bioinformatics 2002;18:207-8.
20. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-21.
21. Monti S, Savage K, Kutok J, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005;105:1851-61.
22. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-47.
23. Shaffer AL, Rosenwald A, Hurt EM, et al. Signatures of the immune response. Immunity 2001;15:375-85.
24. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003;33:49-54.
25. Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 1998;187:693-702.
26. + T cells in the antitumor immune response. J Exp Med 1998;188:2357-68.
27. + T cells. Immunity 2005;22:371-83.
28. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8:68-74.
29. Affymetrix Inc. GeneChip expression analysis: data analysis fundamentals. http://www.affymetrix.com/support/downloads/manuals/ data_analysis_fundamentals_manual.pdf. Accessed August 11, 2005.
30. Ogden CA, Pound JD, Batth BK, et al. Enhanced apoptotic cell clearance capacity and B cell survival factor production by IL-10-activated macrophages: implications for Burkitt's lymphoma. J Immunol 2005;174:3015-23.
31. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002;23:549-55.
32. Rimsza LM, Roberts RA, Campo E, et al. Loss of major histocompatibility class II expression in non-immune privileged site diffuse large B cell lymphoma is highly coordinated and not due to chromosomal deletions. Blood 2006;107:1101-7.